TopNewsOn
Politics

The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

Eric Wargotz, opinion contributor·The Hill·November 19, 2026
Mostly Factual · factual reporting (3 of 5)Outlet ratings by Media Bias/Fact Check

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

Read the full story at The Hill →
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters — TopNewsOn